Becton, Dickinson and Company (BDX)
SEC filings, financial facts, source resources, and Goglides workspace context for Becton, Dickinson and Company.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
2Results1Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
DVLT June 2026 deep dive: the $2B headline is not the thesis yetXORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing risk
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
BD: the medtech reset has to turn hospital scale back into cleaner earnings
Becton Dickinson reported FY2025 revenue of $21.84 billion and Q2 FY2026 revenue of $4.71 billion, with the official record tying the thesis to medtech scale, portfolio reshaping, hospital demand, margin recovery, debt and cash conversion.
Open